Targeting cardiac fibrosis with engineered T cells
Haig Aghajanian(Therapeutics Clinical Research), Jonathan A. Epstein(University of Pennsylvania), Wei Han(Harbin Medical University), Steven Μ. Albelda(University of Pennsylvania), Aidan S. Hancock(California Institute for Regenerative Medicine), Carl H. June(University of Pennsylvania), James Monslow(University of Pennsylvania), Albert Lo(University of Pennsylvania), Rajan Jain(Penn Center for AIDS Research), Joel G. Rurik(Karolinska Institutet), Kenneth Bedi(University of Pennsylvania), Ricardo Linares-Saldana(California Institute for Regenerative Medicine), Michael S. Leibowitz(Children's Hospital of Philadelphia), Dagmar Wirth(Helmholtz Centre for Infection Research), Cheryl L. Smith(California Institute for Regenerative Medicine), Kendra S. McDaid(University of Pennsylvania), Michael P. Morley(University of Pennsylvania), Nikhita Bolar(California Institute for Regenerative Medicine), Tōru Kimura(Josai University), Charles‐Antoine Assenmacher(University of Pennsylvania), John Scholler(University of Pennsylvania), Li Li(Yantai University), Kenneth B. Margulies(Temple University), Tao Wang(Pfizer (United States)), Ellen Puré(University of the Sciences)
Cited by 799
Related Papers
Adhesion molecules and inflammatory injury
|The FASEB Journal|1994|1k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure
|Nature Communications|2020|924
CAR T Cell Therapy for Solid Tumors
|Annual Review of Medicine|2016|866
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833